# A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)

> **NCT04959851** · — · COMPLETED · sponsor: **Takeda** · enrollment: 185 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Colitis, Ulcerative
- Crohns Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04959851
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-02
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959851, "A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04959851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*